Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report

RATIONALE: Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jin-Yan, Tong, Fan, Gu, Fei-Fei, Liu, Yang-Yang, Zeng, Yu-Lan, Hong, Xiao-Hua, Zhang, Kai, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457885/
https://www.ncbi.nlm.nih.gov/pubmed/28538405
http://dx.doi.org/10.1097/MD.0000000000006985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457885/
https://www.ncbi.nlm.nih.gov/pubmed/28538405
http://dx.doi.org/10.1097/MD.0000000000006985

Ejemplares similares